Sequential administration of interferon γ and interleukin-2 in metastatic renal cell carcinoma:: results of a phase II trial

被引:14
作者
Schmidinger, M
Steger, GG
Wenzel, C
Locker, GJ
Brodowicz, T
Budinsky, AC
Wiltschke, C
Kramer, G
Marberger, M
Zielinski, CC
机构
[1] Dept Med 1, Div Oncol, A-1090 Vienna, Austria
[2] Univ Hosp Vienna, Dept Urol, Vienna, Austria
[3] Dept Med 1, Chair Med Expt Oncol, Vienna, Austria
[4] Ludwig Boltzmann Inst Clin Expt Oncol, Vienna, Austria
关键词
renal cell cancer; cytokines; interferon gamma; interleukin-2; metastatic RCC;
D O I
10.1007/s002620000128
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Because of the known efficacy of several cytokines in the treatment of advanced renal cell cancer (RCC), we have conducted a phase II trial of the efficacy and toxicity of subcutaneous interferon gamma (IFN gamma) and interleukin-2 (IL-2). Methods: 63 patients with progressive metastatic RCC were treated with 100 mu g recombinant IFN gamma 1b administered three times weekly during weeks 1 and 2 and with 4.5 MU recombinant IL-2 administered on 4 consecutive days during weeks 3 and 4, every 6 weeks. Results: 11% of patients had an objective response (CR: 3%, PR: 8%), 33% had SD. Toxicity was generally mild. The median duration of remissions (CR + PR) was 9.6 months; the median duration of SD 8 months. A significant survival benefit was evident at a median observation time of 51 months for patients (44%) responding to therapy (P < 0.0001). Conclusions: we conclude that sequential treatment with IFN gamma and IL-2 may prolong survival in patients with metastatic RCC responding to therapy.
引用
收藏
页码:395 / 400
页数:6
相关论文
共 34 条
[1]   RANDOMIZED PHASE-II TRIAL OF HIGH-DOSE INTERLEUKIN-2 EITHER ALONE OR IN COMBINATION WITH INTERFERON-ALFA-2B IN ADVANCED RENAL-CELL CARCINOMA [J].
ATKINS, MB ;
SPARANO, J ;
FISHER, RI ;
WEISS, GR ;
MARGOLIN, KA ;
FINK, KI ;
RUBINSTEIN, L ;
LOUIE, A ;
MIER, JW ;
GUCALP, R ;
SOSMAN, JA ;
BOLDT, DH ;
DOROSHOW, JH ;
ARONSON, FR ;
SZNOL, M .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :661-670
[2]  
ATZPODIEN J, 1997, P ASCO, V16, pA326
[3]   SUCCESSFUL TREATMENT OF METASTATIC RENAL-CELL CARCINOMA WITH A BIOLOGICALLY-ACTIVE DOSE OF RECOMBINANT INTERFERON-GAMMA [J].
AULITZKY, W ;
GASTL, G ;
AULITZKY, WE ;
HEROLD, M ;
KEMMLER, J ;
MULL, B ;
FRICK, J ;
HUBER, C .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (12) :1875-1884
[4]   Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: Clinical results and immunologic correlates of response [J].
Bukowski, RM ;
Olencki, T ;
Wang, Q ;
Peereboom, D ;
Budd, GT ;
Elson, P ;
Sandstrom, K ;
Tuason, L ;
Rayman, P ;
Tubbs, R ;
McLain, D ;
Klein, E ;
Novick, A ;
Finke, J .
JOURNAL OF IMMUNOTHERAPY, 1997, 20 (04) :301-311
[5]  
DILLMAN RO, 1993, CANCER, V71, P2358, DOI 10.1002/1097-0142(19930401)71:7<2358::AID-CNCR2820710730>3.0.CO
[6]  
2-M
[7]   PHASE-II TRIAL OF LOW-DOSE GAMMA-INTERFERON IN METASTATIC RENAL-CELL CARCINOMA [J].
ELLERHORST, JA ;
KILBOURN, RG ;
AMATO, RJ ;
ZUKIWSKI, AA ;
JONES, E ;
LOGOTHETIS, CJ .
JOURNAL OF UROLOGY, 1994, 152 (03) :841-845
[8]   CONCOMITANT ADMINISTRATION OF RECOMBINANT HUMAN INTERLEUKIN-2 AND RECOMBINANT INTERFERON ALFA-2A - AN ACTIVE OUTPATIENT REGIMEN IN METASTATIC RENAL-CELL CARCINOMA [J].
FIGLIN, RA ;
BELLDEGRUN, A ;
MOLDAWER, N ;
ZEFFREN, J ;
DEKERNION, J .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :414-421
[9]   RECOMBINANT INTERFERON ALFA-2A IN METASTATIC RENAL-CELL CARCINOMA - ASSESSMENT OF ANTITUMOR-ACTIVITY AND ANTI-INTERFERON ANTIBODY-FORMATION [J].
FIGLIN, RA ;
DEKERNION, JB ;
MUKAMEL, E ;
PALLERONI, AV ;
ITRI, LM ;
SARNA, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1604-1610
[10]   RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY [J].
FYFE, G ;
FISHER, RI ;
ROSENBERG, SA ;
SZNOL, M ;
PARKINSON, DR ;
LOUIE, AC .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :688-696